Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma

被引：0
|
作者：
Mi Na Kim
Seung Min Lee
Jin Sung Kim
Seong Gyu Hwang
机构：
[1] CHA University School of Medicine,Division of Gastroenterology, Department of Internal Medicine, CHA Bundang Medical Center
[2] CHA University,Institute for Clinical Research, CHA Bundang Medical Center
[3] School of Medicine,undefined
[4] CMG Pharmaceutical CO.,undefined
[5] LTD,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; Sorafenib; Dual PI3K/mTOR inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：809 / 817
页数：8
相关论文
共 50 条
  • [1] Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
    Kim, Mi Na
    Lee, Seung Min
    Kim, Jin Sung
    Hwang, Seong Gyu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 809 - 817
  • [2] Preclinical Efficacy of Novel Dual PI3K/mTOR Inhibitor CMG002 As Potential Anti-Hepatocellular Carcinoma Agent
    Kim, Mi Na
    Lee, Seung Min
    Hwang, Seong-Gyu
    HEPATOLOGY, 2018, 68 : 1266A - 1266A
  • [3] A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
    Choi, Hye Joung
    Heo, Jin Hyung
    Park, Ju Yeon
    Jeong, Ju Yeon
    Cho, Hyeon Ju
    Park, Kyung Soon
    Kim, Se Hwa
    Moon, Yong Wha
    Kim, Jin Sung
    An, Hee Jung
    GYNECOLOGIC ONCOLOGY, 2019, 153 (01) : 135 - 148
  • [4] The Role of PI3K/mTOR Inhibition in Combination with Sorafenib in Hepatocellular Carcinoma Treatment
    Gedaly, Roberto
    Angulo, Paul
    Chen, Changguo
    Creasy, Kate Townsend
    Spear, Brett T.
    Hundley, Jonathan
    Daily, Michael F.
    Shah, Malay
    Evers, B. Mark
    ANTICANCER RESEARCH, 2012, 32 (07) : 2531 - 2536
  • [5] The Role of PI3K/mTOR Dual Inhibition in Combination with Sorafenib on Hepatocellular Carcinoma and Liver Cancer Stem Cell Treatment
    Gedaly, R.
    Angulo, P.
    Chen, C.
    Creasy, K. T.
    Spear, B. T.
    Hundley, J.
    Daily, M. F.
    Shah, M.
    Evers, B. M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 199 - 199
  • [6] Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    Roulin, Didier
    Waselle, Laurent
    Dormond-Meuwly, Anne
    Dufour, Marc
    Demartines, Nicolas
    Dormond, Olivier
    MOLECULAR CANCER, 2011, 10
  • [7] Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    Didier Roulin
    Laurent Waselle
    Anne Dormond-Meuwly
    Marc Dufour
    Nicolas Demartines
    Olivier Dormond
    Molecular Cancer, 10
  • [8] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Maria Serova
    Armand de Gramont
    Annemilaï Tijeras-Raballand
    Célia Dos Santos
    Maria Eugenia Riveiro
    Khemaies Slimane
    Sandrine Faivre
    Eric Raymond
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1297 - 1307
  • [9] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Serova, Maria
    de Gramont, Armand
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Riveiro, Maria Eugenia
    Slimane, Khemaies
    Faivre, Sandrine
    Raymond, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1297 - 1307
  • [10] GSK458, a novel oral dual PI3K/mTOR Inhibitor, is effective in preclinical model of T-cell lymphoma alone and in combination therapies
    Gu, Juan J.
    Yang, Lianjuan
    He, Jing
    Shen, Weina
    Mavis, Cory
    Hernandez-Ilizaliturri, Francisco
    CANCER RESEARCH, 2019, 79 (13)
12345